These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Pharmacological considerations in the treatment of glaucoma. Fiscella RG Manag Care; 2002 Jan; 11(1 Suppl):16-20; discussion 24-7. PubMed ID: 11842587 [No Abstract] [Full Text] [Related]
28. A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients. Martin E; Martinez-de-la-Casa JM; Garcia-Feijoo J; Troyano J; Larrosa JM; Garcia-Sanchez J Eye (Lond); 2007 Feb; 21(2):164-8. PubMed ID: 16254590 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand. Wanichwecha-Rungruang B; Iemsomboon W J Med Assoc Thai; 2005 Sep; 88(9):1228-35. PubMed ID: 16536109 [TBL] [Abstract][Full Text] [Related]
30. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy. Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592 [TBL] [Abstract][Full Text] [Related]
31. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma. Yildirim N; Sahin A; Gultekin S J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382 [TBL] [Abstract][Full Text] [Related]
32. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients--a European perspective. Tuil E; Hommer AB; Poulsen PB; Christensen TL; Buchholz P; Walt J; Holmstrom S Int J Clin Pract; 2005 Sep; 59(9):1011-6. PubMed ID: 16115174 [TBL] [Abstract][Full Text] [Related]
33. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Kroll DM; Schuman JS Am J Ophthalmol; 2002 Mar; 133(3):401-3. PubMed ID: 11860979 [TBL] [Abstract][Full Text] [Related]
34. A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy. Christensen TL; Poulsen PB; Holmstrom S; Walt JG; Vetrugno M Curr Med Res Opin; 2005 Nov; 21(11):1837-44. PubMed ID: 16307705 [TBL] [Abstract][Full Text] [Related]
35. A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension. Trattler W; Noecker RJ; Earl ML Adv Ther; 2008 Mar; 25(3):179-89. PubMed ID: 18351298 [TBL] [Abstract][Full Text] [Related]
36. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials. Varma R; Hwang LJ; Grunden JW; Bean GW Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194 [TBL] [Abstract][Full Text] [Related]
38. A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost. Simmons ST; Bernstein P; Hollander DA Am J Ophthalmol; 2008 Sep; 146(3):473-7. PubMed ID: 18561893 [TBL] [Abstract][Full Text] [Related]